Challenges in Diagnosing Intermediate Maple Syrup Urine Disease by Newborn Screening and Functional Validation of Genomic Results Imperative for Reproductive Family Planning
暂无分享,去创建一个
J. Fletcher | S. Balasubramaniam | G. Ho | V. Wiley | B. Bennetts | M. Fuller | B. Devanapalli | M. Sajeev | B. P. Sankaran | A. Tolun | Sharon J. Chin | Bea Gutierrez
[1] I. Knerr,et al. Maple syrup urine disease: Clinical outcomes, metabolic control, and genotypes in a screened population after four decades of newborn bloodspot screening in the Republic of Ireland , 2020, Journal of inherited metabolic disease.
[2] P. Blackburn,et al. Maple syrup urine disease: mechanisms and management , 2017, The application of clinical genetics.
[3] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[4] J. Christodoulou,et al. An improved ultra performance liquid chromatography-tandem mass spectrometry method for the determination of alloisoleucine and branched chain amino acids in dried blood samples , 2011, Annals of clinical biochemistry.
[5] G. Homanics,et al. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease , 2008, Brain : a journal of neurology.
[6] K. Bhattacharya,et al. Newborn screening may fail to identify intermediate forms of maple syrup urine disease , 2006, Journal of Inherited Metabolic Disease.
[7] S. Blaser,et al. Atypical phenotype in a boy with a maple syrup urine disease , 2006, Journal of Inherited Metabolic Disease.
[8] E. Puffenberger,et al. Diagnosis and treatment of maple syrup disease: a study of 36 patients. , 2002, Pediatrics.
[9] U. Wendel,et al. Whole-Body l-Leucine Oxidation in Patients with Variant Form of Maple Syrup Urine Disease , 2001, Pediatric Research.
[10] D. Chuang,et al. Maple syrup urine disease: it has come a long way. , 1998, The Journal of pediatrics.
[11] D. Chuang,et al. E2 transacylase-deficient (type II) maple syrup urine disease. Aberrant splicing of E2 mRNA caused by internal intronic deletions and association with thiamine-responsive phenotype. , 1997, The Journal of clinical investigation.
[12] G. Lynch,et al. Maple Syrup Urine Disease , 1964, Journal of mental deficiency research.
[13] C. Dionisi-Vici,et al. Branched-chain Organic Acidurias /Acidaemias , 2012 .
[14] D. Millington,et al. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. , 1995, Clinical chemistry.